Cargando…

Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study

OBJECTIVE: In the Phase III PAOLA study (clinicaltrials.gov: NCT01137682), enrolled patients had uncontrolled acromegaly despite ≥6 months of octreotide/lanreotide treatment before study start. More patients achieved biochemical control with long-acting pasireotide versus continued treatment with oc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colao, Annamaria, Bronstein, Marcello D, Brue, Thierry, De Marinis, Laura, Fleseriu, Maria, Guitelman, Mirtha, Raverot, Gerald, Shimon, Ilan, Fleck, Jürgen, Gupta, Pritam, Pedroncelli, Alberto M, Gadelha, Mônica R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2020
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222286/ https://www.ncbi.nlm.nih.gov/pubmed/32217809 http://dx.doi.org/10.1530/EJE-19-0762

Ejemplares similares

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
por: Gadelha, Mônica R, et al.
Publicado: (2020)

Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly
por: Schmid, Herbert A., et al.
Publicado: (2016)

Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study
por: Bronstein, Marcello D., et al.
Publicado: (2016)

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
por: Colao, A., et al.
Publicado: (2014)

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
por: Chiloiro, Sabrina, et al.
Publicado: (2021)

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
por: Gadelha, Mônica, et al.
Publicado: (2020)

Pasireotide: a novel treatment for patients with acromegaly
por: Cuevas-Ramos, Daniel, et al.
Publicado: (2016)

Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study
por: Sheppard, Michael, et al.
Publicado: (2014)

SAT-433 Long-Acting Pasireotide Provides Clinical Benefit to Patients with Uncontrolled Acromegaly over Continued Treatment with First‑Generation Somatostatin Analogues (SSAs): Results from Phase 3b, Open-Label Study
por: Gadelha, Mônica, et al.
Publicado: (2019)

Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study
por: Sheppard, Michael, et al.
Publicado: (2015)

Pasireotide in the Personalized Treatment of Acromegaly
por: Puig-Domingo, Manel, et al.
Publicado: (2021)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

Management of acromegaly in Latin America: expert panel recommendations
por: Barkan, Ariel, et al.
Publicado: (2009)

Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study
por: Petersenn, Stephan, et al.
Publicado: (2013)

SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs
por: Chiloiro, Sabrina, et al.
Publicado: (2019)

Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly
por: Marques, Nelma Veronica, et al.
Publicado: (2023)

THU066 An 8-year Interim Report Of The B2412 Study, An Open-label, Multicenter Pasireotide Rollover Study For Patients Who Continued To Receive Benefit From Pasireotide At Completion Of An Earlier Trial
por: Gadelha, Mônica, et al.
Publicado: (2023)

Erratum to: Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study
por: Petersenn, Stephan, et al.
Publicado: (2013)

Patient-focussed outcomes in acromegaly
por: Guitelman, Mirtha, et al.
Publicado: (2013)

Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly
por: Silverstein, Julie M.
Publicado: (2016)

Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide
por: Puglisi, Soraya, et al.
Publicado: (2020)

Safety and tolerability of pasireotide long-acting release in acromegaly—results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study
por: Fleseriu, Maria, et al.
Publicado: (2016)

Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience
por: Gadelha, Mônica, et al.
Publicado: (2023)

Cost-Utility of Acromegaly Pharmacological Treatments in a French Context
por: Brue, Thierry, et al.
Publicado: (2021)

Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
por: Colao, Annamaria, et al.
Publicado: (2015)

A Conversation With Paola D’Angelo
por: Patel, Prachi
Publicado: (2018)

Signs and symptoms of acromegaly at diagnosis: the physician’s and the patient’s perspectives in the ACRO-POLIS study
por: Caron, Philippe, et al.
Publicado: (2018)

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
por: Feelders, Richard A., et al.
Publicado: (2023)

Pasireotide: successful treatment of a sparsely granulated tumour in a resistant case of acromegaly
por: Amarawardena, W K M G, et al.
Publicado: (2017)

Correction to: Signs and symptoms of acromegaly at diagnosis: the physician’s and the patient’s perspectives in the ACRO-POLIS study
por: Caron, Philippe, et al.
Publicado: (2018)

Acromegaly in the elderly patient
por: Jallad, Raquel S., et al.
Publicado: (2019)

Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing’s disease: 12-month, Phase III pasireotide study
por: Findling, James W., et al.
Publicado: (2016)

The Biochemical Diagnosis of Acromegaly
por: Akirov, Amit, et al.
Publicado: (2021)

Monitoring Patient Improvement Parameters following Pasireotide Treatment in Cushing's Disease
por: Yedinak, Chris, et al.
Publicado: (2013)

Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations
por: Colao, Annamaria, et al.
Publicado: (2013)

More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY
por: Fleseriu, Maria, et al.
Publicado: (2021)

Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study
por: Lasolle, Hélène, et al.
Publicado: (2019)

Successful Therapy Using Pasireotide Long-acting Release for Cushing's Disease Merged with Biochemical Acromegaly
por: Fukunaga, Kensaku, et al.
Publicado: (2020)

Treatment Patterns, Adherence, Persistence, and Health Care Resource Utilization in Acromegaly: A Real-World Analysis
por: Fleseriu, Maria, et al.
Publicado: (2023)

Resolution of Cyclicity After Pasireotide LAR in a Patient With Cushing Disease
por: Machado, Márcio Carlos, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5kdlfdg2qb8n0cg1avivu7ols1